These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 24150924)

  • 1. Comparative efficacies of fluoxetine and paroxetine in major depression across varying acute-phase treatment periods: a meta-analysis.
    Wang Y; Yu L; Xie J; Chen J; Wei Q
    Asia Pac Psychiatry; 2014 Dec; 6(4):353-62. PubMed ID: 24150924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression.
    Fava M; Rosenbaum JF; Hoog SL; Tepner RG; Kopp JB; Nilsson ME
    J Affect Disord; 2000 Aug; 59(2):119-26. PubMed ID: 10837880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy and acceptability of antidepressant treatment in poststroke depression: a multiple-treatments meta-analysis.
    Sun Y; Liang Y; Jiao Y; Lin J; Qu H; Xu J; Zhao C
    BMJ Open; 2017 Aug; 7(8):e016499. PubMed ID: 28775189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluoxetine versus other types of pharmacotherapy for depression.
    Magni LR; Purgato M; Gastaldon C; Papola D; Furukawa TA; Cipriani A; Barbui C
    Cochrane Database Syst Rev; 2013 Jul; 2013(7):CD004185. PubMed ID: 24353997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Venlafaxine extended-release: a review of its use in the management of major depression.
    Wellington K; Perry CM
    CNS Drugs; 2001; 15(8):643-69. PubMed ID: 11524036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching Selective Serotonin Reuptake Inhibitors in Adolescents with Selective Serotonin Reuptake Inhibitor-Resistant Major Depressive Disorder: Balancing Tolerability and Efficacy.
    Strawn JR; Mills JA; Croarkin PE
    J Child Adolesc Psychopharmacol; 2019 May; 29(4):250-255. PubMed ID: 30810350
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical practice guidelines for depression in young people.
    Jureidini JN; Tonkin AL
    Med J Aust; 2003 Mar; 178(6):300; author reply 300-2. PubMed ID: 12633493
    [No Abstract]   [Full Text] [Related]  

  • 8. Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo.
    Shelton C; Entsuah R; Padmanabhan SK; Vinall PE
    Int Clin Psychopharmacol; 2005 Jul; 20(4):233-8. PubMed ID: 15933485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial.
    Kroenke K; West SL; Swindle R; Gilsenan A; Eckert GJ; Dolor R; Stang P; Zhou XH; Hays R; Weinberger M
    JAMA; 2001 Dec; 286(23):2947-55. PubMed ID: 11743835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefits and harms of pediatric antidepressant medications.
    Edwards JL; Kirk KK; Midha CK
    JAMA; 2007 Aug; 298(6):626-7; author reply 627. PubMed ID: 17684183
    [No Abstract]   [Full Text] [Related]  

  • 11. Fluoxetine versus other types of pharmacotherapy for depression.
    Cipriani A; Brambilla P; Furukawa T; Geddes J; Gregis M; Hotopf M; Malvini L; Barbui C
    Cochrane Database Syst Rev; 2005 Oct; (4):CD004185. PubMed ID: 16235353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Duloxetine versus other anti-depressive agents for depression.
    Cipriani A; Koesters M; Furukawa TA; Nosè M; Purgato M; Omori IM; Trespidi C; Barbui C
    Cochrane Database Syst Rev; 2012 Oct; 10(10):CD006533. PubMed ID: 23076926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Course and cost of treatment for depression with fluoxetine, paroxetine, and sertraline.
    Russell JM; Berndt ER; Miceli R; Colucci S; Grudzinski AN
    Am J Manag Care; 1999 May; 5(5):597-606. PubMed ID: 10537866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of Paroxetine for Poststroke Depression: A Meta-Analysis.
    Li L; Han Z; Li L; Han L; Yan B
    J Stroke Cerebrovasc Dis; 2020 May; 29(5):104664. PubMed ID: 32093988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder.
    Thase ME; Pritchett YL; Ossanna MJ; Swindle RW; Xu J; Detke MJ
    J Clin Psychopharmacol; 2007 Dec; 27(6):672-6. PubMed ID: 18004135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment.
    Judge R; Parry MG; Quail D; Jacobson JG
    Int Clin Psychopharmacol; 2002 Sep; 17(5):217-25. PubMed ID: 12177584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy, acceptability, and safety of medicinal, cognitive-behavioral therapy, and placebo treatments for acute major depressive disorder in children and adolescents: a multiple-treatments meta-analysis.
    Ma D; Zhang Z; Zhang X; Li L
    Curr Med Res Opin; 2014 Jun; 30(6):971-95. PubMed ID: 24188102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder.
    Trivedi MH; Wan GJ; Mallick R; Chen J; Casciano R; Geissler EC; Panish JM
    J Clin Psychopharmacol; 2004 Oct; 24(5):497-506. PubMed ID: 15349005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials.
    Eyding D; Lelgemann M; Grouven U; Härter M; Kromp M; Kaiser T; Kerekes MF; Gerken M; Wieseler B
    BMJ; 2010 Oct; 341():c4737. PubMed ID: 20940209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder.
    Chouinard G; Saxena B; Bélanger MC; Ravindran A; Bakish D; Beauclair L; Morris P; Vasavan Nair NP; Manchanda R; Reesal R; Remick R; O'Neill MC
    J Affect Disord; 1999 Jul; 54(1-2):39-48. PubMed ID: 10403145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.